Chronic myeloid leukemia (CML) can be effectively treated inhibiting the disease-causing BCR::ABL1 kinase by tyrosine kinase inhibitors (TKIs). Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.